CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis

  • End date
    Aug 30, 2026
  • participants needed
  • sponsor
    Beijing 302 Hospital
Updated on 21 September 2021
platelet count
liver transplant
stereotactic body radiation therapy
tumour thrombus


The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.

Condition HEPATIC NEOPLASM, liver cell carcinoma, HEPATOCELLULAR CARCINOMA, Adenocarcinoma, Malignant Adenoma, Liver Cancer
Treatment Cyberknife stereotactic body radiation therapy
Clinical Study IdentifierNCT04512833
SponsorBeijing 302 Hospital
Last Modified on21 September 2021


Yes No Not Sure

Inclusion Criteria

Primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
Unfeasible or refusing to undergo other treatments
Residual normal liver volume 700 cc
With decompensated cirrhosis (Child-Pugh B or C classification)
Without portal vein tumor thrombus
Eastern Cooperative Oncology Group (ECOG) score 0-1
Distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm
Rejecting other therapies such as resection, liver transplantation, etc
Platelet count50 109/L, white blood count1.5 109/L
Patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative

Exclusion Criteria

With Tumor thrombus
With extrahepatic metastasis
With lymph node involvement
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note